Revenue
2020
2021
Atea Pharmaceuticals, Inc. (AVIR)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $351.4M | $48.6M | — | — |
| Research & development | $148.0M | $144.1M | $114.2M | $81.9M | $167.2M | $38.0M | $10.2M | $6.7M |
| Operating expenses | $180.9M | $192.9M | $164.2M | $130.7M | $213.0M | $59.7M | $14.6M | $9.5M |
| Operating income | −$180.9M | −$192.9M | −$164.2M | −$130.7M | $138.4M | −$11.0M | −$14.6M | −$9.5M |
| EBITDAderived | −$180.5M | −$192.5M | −$163.7M | −$130.4M | $138.4M | −$11.0M | −$14.6M | −$9.5M |
| Net income | −$158.3M | −$168.4M | −$136.0M | −$115.9M | $121.2M | −$10.9M | −$14.0M | −$9.1M |
| Basic EPSper diluted share | -$1.94 | -$2.00 | -$1.63 | -$1.39 | $1.46 | -$0.51 | -$1.39 | -$0.90 |
| Diluted EPSper diluted share | -$1.94 | -$2.00 | -$1.63 | -$1.39 | $1.37 | -$0.51 | -$1.39 | -$0.90 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 18, 2026Form 4/A | Murphy Polly A.Director | BuyCommon Stock | 6.1K | $4.17 | $25.4K | 92.1K |
| May 18, 2025Form 4 | Murphy Polly A.Director | BuyCommon Stock | 6.1K | $4.17 | $25.4K | 92.1K |
| Jan 16, 2025Form 4/A | BERGER FRANKLIN MDirector | BuyCommon Stock | 10.0K | $3.36 | $33.6K | 476.9K |
| Jan 16, 2025Form 4 | BERGER FRANKLIN MDirector | BuyCommon Stock | 10.0K | $3.36 | $33.6K | 476.9K |
| Jan 15, 2025Form 4/A | BERGER FRANKLIN MDirector | BuyCommon Stock | 15.0K | $3.19 | $47.9K | 466.9K |